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SubStance uSe admiSSionS trend among older adultS
Chhatre S., Metzger D.S., Jayadevappa R.
University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVES: To study the longitudinal trend (between 2000 and 2012) in substance 
use admissions among older adults, i.e., those aged 55 or older. METHODS: Using 
the Treatment Episode Data Set - Admissions (TEDS-A) for the period between 2000 
and 2012, we analyzed the trend in substance use admissions reported for older 
adults. Substance use admissions for older adults as a proportion of total sub-
stance use admissions were compared. Also, the trend in admission for primary 
substances such as cocaine/crack, marijuana/hashish, heroin, non-prescription 
methadone, other opiates and synthetics, methamphetamine, and benzodiazepines 
was compared. RESULTS: Of the total admissions for substance use in 2000, 3.4 
percent were attributable to older adults. Over time, there was a increase in this 
proportion and in 2012, 7.0 percent of all substance use admissions were accounted 
for by older adults. Older adults also exhibited sharp escalation in proportion of 
admissions between 2000-2012 where primary substance that led to admission 
was cocaine/crack (63% increase), marijuana/hashish (150% increase ), heroin (26% 
increase), non-prescription methadone (200% increase), other opiates and synthet-
ics (221% increase), methamphetamine (275% increase), and benzodiazepines (67% 
increase). CONCLUSIONS: It is important to note that though the total number of 
substance use admissions between 2000 and 2012 changed only a little, the propor-
tion of admissions attributable to older adults increased greatly. Among older adults, 
substance use is an important psychosocial co-comorbidity. Admissions for certain 
types of substances appear to be on the rise . Presence of substance use translates 
into treatment need. It can affect health outcomes and complicate management 
of other co-morbid conditions. Therefore, a surge in substance use in older persons 
coupled with aging of the US population has substantial implications for the entire 
healthcare system. There is an urgent need for appropriate preventive and treat-
ment polices aimed specifically towards older adults with a substance use disorder.
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antimicrobial utiliSation in Slovak HoSPitalS
Snopkova M.1, Antlova K.1, Majtas J.2
1Faculty of Pharmacy Comenius University, Bratislava, Slovak Republic, 2Comenius University, 
Bratislava, Slovak Republic
OBJECTIVES: Analysis of the consumption of antibiotics plays a very important 
role in hospital care, since it allows the identification of areas where measures to 
improve the suitability for use and rationalization of resources should be adopted, 
stimulating improve the quality and development of surveillance strategies anti-
biotic resistance. The consumption of antibiotics in Slovak hospitals is still high 
compared with the other European countries. The aim of the study was to analyze 
the utilisation of antibiotics in the hospital sector in Slovakia. METHODS: Drug’s 
expenditure derived from the State Institute of Drug Control. Antibiotic drug con-
sumption was expressed as number of packages and as DDDs per 1000 inhabitants 
per day (DID). Data were analyzed according to ATC classification. RESULTS: During 
the period 2011 – 2014 was increased consumption of antibiotics - expressed as 
number of packages - in the ATC group J01D, in the community sector (primary 
care sector). By contrast, in the hospital pharmacies, the consumption gradually 
decreases. The Macrolides (J01F), one of the most prescribed antibiotics in commu-
nity sector reach 30% of the total volume consumed antibiotics in the community, 
in hospital sector but only 5%. While consumption of penicillins in hospital sector is 
increasing slightly (5% during the period), in the group of other beta-lactam antibiot-
ics, decrease (10 % during the period). CONCLUSIONS: According of the antibiotics 
costs demonstrated the development of consumption during the analyzed period 
decreasing trend. The decreasing consumption of antibiotics in community sector 
leads to increase of consumptions in hospital sector. The other analysis of consump-
tion at the hospital level should help health care providers to improve antibiotic use.
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OBJECTIVES: Drug-related problems (DRPs), prescribing pattern (PP) and poly-
pharmacy are identified as important risk factors in pharmaceutical care plan-
ning. This study was aimed to evaluate DRPs, PP and poly pharmacy issues in 
Pakistan. METHODS: A drug utilization-pattern regarding DRPs, PP and polyphar-
macy was evaluated at filling and refilling of the prescriptions written by registered 
medical practitioners and specialized physicians at local community pharmacies’ 
in a province, the Punjab, Pakistan. A stratified sample manner was adopted for 
selecting different community pharmacies. All of the prescriptions were ana-
lyzed according to WHO standard treatment guidelines for DRPs, PP and polyp-
harmacy. RESULTS: Among 900 observed prescriptions from different cities of the 
province, several DRPs, vague PP and polypharmacy issues were observed. Unfair 
numbers and types of drugs than the WHO recommendations were prescribed for 
each patient. Mean number of drugs in a single prescription were 5.0 (+1.6). The 
worth of prescribing indicators was much more than the WHO standard indica-
tors. A significant number of medicines (89%) were written in their brand names. 
Furthermore, the repeatedly prescribed medicines were antibiotics (55.1%), anxiolyt-
ics (22.4%), and corticosteroids (26%). CONCLUSIONS: Physicians’ adherence to the 
WHO standard prescribing guidelines was poor. Effecting apposite administrative 
dosing would be used to identify potential problem cases. The objective of this 
study was to evaluate the criteria being discussed by in this potential measure in 
Mississippi Medicaid. METHODS: A retrospective study was done using Mississippi 
Medicaid claims data for 2013. Beneficiaries were included if enrolled the entire 
year, had 1+ prescription for an opioid in the Center for Disease Control Morphine 
Milligram Equivalent Table, were age 19+, and they did not have any claims with 
diagnoses of sickle cell anaemia or cancer, were not dual eligible or in long term 
care. Morphine Equivalent Dose (MED) values were calculated for all prescriptions. 
Cut-off values of 120mg and 100mg MED were examined with sensitivity analysis 
for number of days at or above the cut-off. RESULTS: 1.37% and 2.24% of the benefi-
ciaries received prescriptions for opioids > 100mg MED for ≥ 60 and 30≥ consecutive 
days. 1.72% and 2.70% of the beneficiaries were found to receive prescriptions of 
opioids > 120mg MED for ≥ 60 and 30≥ consecutive days. Approximately, 1.77% of 
beneficiaries having an opioids prescription claims are consuming an MED greater 
than 120mg for more than 31 days indicating issues with their opioid consump-
tion pattern. 12.5% of beneficiaries having > 100mg MED for 30+ consecutive days 
were doctor shopping (using 4+ pharmacies and 4+ prescribers). CONCLUSIONS: 
Beneficiaries with high MED are at risk of becoming abusers, if they are not already. 
Use of MED limits in drug utilization review is a good method for identifying ben-
eficiaries at risk of becoming abusers. Combining doctor shopping with high MED 
can be used to identify potential abusers for intervention.
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OBJECTIVES: Bioequivalence studies are required for approval of generic medica-
tions and are regarded as a reliable methodology to evaluate equivalence of generic 
vs. branded products. However, recent issues with a few newly-launched generics 
highlight the need for post-marketing monitoring of generic medicines. Real world 
evidence uniquely available in pharmacy claims data can provide early detection of 
bioequivalence issues well before conventional methods (i.e. MedWatch).This study 
presents an analytic approach that uses pharmacy claims data to monitor possible 
bioequivalence issues with one generic version of the anti-depressant bupropion 
that was finally withdrawn from the market after studies failed to show bioequiva-
lence with the branded product. METHODS: Patient-level pharmacy claims data 
from Express Scripts, a pharmacy benefit manager (PBM) with over 90 million 
Americans, was used in a retrospective study evaluating patient persistence before 
discontinuation. Persistence was defined as the days from medication initiation to 
an instance of 45 days without therapy. Evaluations were done separately for 150 
and 300 mg bupropion and by manufacturer. RESULTS: With the 300 mg bupropion 
where bioequivalence was questioned, the percent of patients non-persistent at day 
360 was notably higher for some generic versions than for others. Manufacturer-
specific drop off rates were more similar for the 150 mg version where bioequiva-
lence was not questioned. Declining persistency among other generic providers 
was also observed, and could be due to awareness of the bioequivalence concerns 
among health professionals. CONCLUSIONS: The results demonstrate a decline 
in utilization of a specific generic anti-depressant medication that subsequently 
failed bioequivalence testing, supporting the use of large PBM claims databases with 
access to real-time product utilization details. Leveraging consumer information 
early in the generic launch process can provide insights into bioequivalence leading 
to improved patient care through early detection and enhance Health Economic and 
Outcomes Research (HECOR) and Market Researcher Post Launch strategy.
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OBJECTIVES: Just over 7 million Americans enrolled in private insurance through 
the new health insurance exchanges in 2014. The exchange plans are required to 
cover essential health benefits, including prescription drugs, although the generos-
ity of prescription drug coverage in exchange plans has not been well described, 
nor compared to employer-sponsored insurance. METHODS: We examined the 27 
federally facilitated exchanges and 7 partnership exchanges, for which character-
istics of all plans on the exchanges were publicly available from data.gov for 2014. 
For comparison we also provide additional results for the 2015 plans. We com-
pared the exchanges with data from the Kaiser Family Foundation/Health Research 
Educational Trust’s annual employer survey. Descriptive analyses of exchange plans 
quantifying plan characteristics including extent of copayments or coinsurance, 
number of pharmacy benefit tiers, average copayment/coinsurance in each for-
mulary tier, and deductible amounts. RESULTS: Within the exchanges, we find 
wide variation in the out-of-pocket costs enrollees will face for generic, preferred 
brand, non-preferred brand and specialty drugs, both across metal tiers and across 
plan type within metal tier. Coinsurance is used instead of copayments for many 
drugs in the upper pharmacy formulary tiers (e.g. Specialty drugs). Compared to 
employer sponsored plans, these exchange plans generally have lower premiums, 
but provide less generous coverage. Cost sharing subsidies for low income indi-
viduals may mitigate the higher out of pocket costs found in many silver exchange 
plans. CONCLUSIONS: On average, exchange plans had lower premiums than 
employer-sponsored insurance plans, but higher deductibles and cost sharing for 
prescription drugs. The gold and platinum-level PPO plans were more generous 
than employer-sponsored coverage on average. Decision tools to assist consumers 
in selecting plans on more attributes than just premium will also be key in helping 
individuals avoid high out of pocket burdens.
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and females had almost similar travel time of 2.43 and 2.40 minutes, respectively 
(p= 0.80). Travel time was 2.44 minutes for the patients younger than 65 years and 
2.28 minutes for patients older than 65 years (p= 0.25). CONCLUSIONS: There was 
no major difference in access to pharmacy based on age or gender. Blacks have 
statistically significantly shorter travel time than whites. Future work will examine 
other factors like socioeconomic status.
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Sujkowska G., Jagodzinska-Kalinowska K., Matusewicz W., Zabielska J.
Agency for Health Technology Assessment and Tariff System, Warsaw, Poland
OBJECTIVES: The aim of the analysis was to compare the medicines centrally 
authorised by EMA with reference to their reimbursement in Poland. In Poland, inno-
vative drugs need to be recommended by Agency for Health Technology Assessment 
(AOTM) before the decision about reimbursement is taken by Minister of Health. 
Recommendations issued by AOTM have been based on Manufacturer`s submis-
sion and additional officially published data, including EMA’s data. METHODS: All 
decisions issued by EMA since 1995 connected with new medicines registration 
were analyzed and categorized into therapeutic area. Then it was checked which 
of the drugs found in the EMA’s database were reimbursed in Poland in the years 
2012- 2013. RESULTS: It was found that till the end of December 2014 there were 563 
unique active substance available in EMA’s database. The analysis shows that in 2012 
the reimbursement in Poland was related to 114 active substances registered in EMA, 
which is approx. 20% of all substances in the EMA’s database. A year later 3% (23%) 
more active substances (131) were reimbursed in Poland. Most active substances 
registered in EMA and reimbursed in Poland, belongs to the group ATC: L (antineo-
plastic and immunomodulating medicines). Over 40% of the active ingredients of 
this group registered in EMA were reimbursed in Poland in 2012 and 50% in 2013. 
The second ATC group was A (alimentary tract and metabolism) -12% and group 
B (blood and blood forming organs) -11% (in both years). CONCLUSIONS: Not all 
drugs registered in EMA are reimbursed in Poland. We can conclude that anticancer 
drugs are the most likely to be paid from public sources, then medicines related to 
treatment metabolism and blood disorders. It was found that there was any drug 
reimbursed in Poland registered by EMA in ATC group P (antiparasitic products, 
insecticides and repellents).
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are we really meaSuring acceSS? SyStematic review of acceSS 
meaSureS to medicineS in brazil
Araujo V.E., Izidoro J.B., Guerra-Junior A.a., Dias C.Z., Ascef B.O., Costa C.M., Nascimento R.C., 
Acurcio F.a., Alvares J.
College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil
OBJECTIVES: Access to medicines (ATM) is a key component in enabling and meas-
uring the performance of health systems. This study aims to determine, through a 
systematic literature review, the profile of studies and the results of ATM’s indicators 
in Brazil, according with the dimensions of access proposed by Penchansky and 
Thomas METHODS: A systematic review of observational studies was performed 
using articles located in PUBMED, CENTRAL, LILACS and Essential Medicines and 
Health Products Information Portal (WHO) databases (accessed July 2014), in manual 
search and in grey literature. The methodological quality was assessed using the 
Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies of 
NIH (National Institute of Health - USA). RESULTS: 1482 studies were found and 
28 were included. Among these, 64% evaluated access at the municipal level, 75% 
in the public sector, 50% from the perspective of users, 75% the access to essential 
medicines, 50% evaluated more than one dimension, 82% had indicators related 
to availability. Among all dimensions of ATM 18 different indicators were found. 
The indicator with the greatest utilization rate physical availability (PA) was used 
in 39% of the studies. The results of the indicators were variable, ranged from 30 to 
90.2% for PA and from 2.02 to 18.7 for Median Price Ratio, for example. The quality of 
studies included was considered adequate. CONCLUSIONS: Most of ATM studies in 
Brazil evaluated it in the public sector, assessing essential drugs and using as a data 
source the users. The studies had focus on availability and no studies have assessed 
all dimensions of ATM. The access level was variable between studies. This review 
raises the need to develop a guideline to evaluate ATM that foment comparisons 
and evaluations of the health systems performance through the time.
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acountable care organizationS- an economic Solution to Provide 
quality HealtHcare for medicare PatientS
Patel P.H.
University of the Sciences, philadelphia, PA, USA
OBJECTIVES: Accountable Care Organizations (ACOs) are groups of doctors, hos-
pitals, and other health care providers, who come together voluntarily to give 
coordinated high quality care to their Medicare patients. The objective is to under-
stand how the policy development and implementation is helping to solve the cost 
and quality of the fragmented U.S. healthcare system. METHODS: Knovner and 
Knickman (2011) textbook on Healthcare delivery in the United States elaborates 
on the major issues and concerns facing the U.S. healthcare system was used to 
evaluate the policy perspective and CMS published data was used to compare the 
performance of ACOs. RESULTS: ACO was able to deal with all the major issues 
and concerns pointed by Knovner and Knickman(2011) in the policy perspective. 
CMS published data shows that 360 Medicare ACOs has been established serving 
5.6 million Americans. ACOs in Pioneer ACO model and Medicare Shared Savings 
Program (MSSP) generated over $417 million in savings for Medicare. Quality of Care 
and Patient experience showed improvements in 28 of the 33 quality measures and 
30 of 33 quality measures in Pioneer and MSSP ACOs. Only 3 Pioneer ACO and 1 MSSP 
generated shared losses. CONCLUSIONS: The new program has tried to learn from 
strategies to improve the current PP in Pakistan are warranted. Additionally, there 
is a great need of patient educational programs regarding polypharmacy and the 
treatment they receive. Furthermore, additional studies should be undertaken in 
other provinces of Pakistan in order to understand the country level clinicians’ 
prescribing practices.
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aSSociated witH Herbal medicineS
Bhat B., Dharmagadda S., Nayanabhirama U.
Manipal University, Manipal, India
OBJECTIVES: This study was aimed to know patients’ awareness and knowledge 
about herbal medicines and their Adverse Drug Reactions (ADRs). METHODS: 322 
patients were asked to give responses to the questionnaire which was developed, 
structured and validated. Random convenience sampling method was used for 
selecting the sample size. The study was conducted in Manipal, Karnataka, India. 
The data was evaluated using SPSS and represented in the form of numbers and per-
centages. RESULTS: 96 patients who have not used herbal medicines were excluded 
from the study. Majority of the patients’ were in the age group of 25-44 (46.3%) 
years and 45-64 (38.8%) years out of which males (54.3%) outnumbered females 
(45.7%). Majority of them were using ayurvedic medicines (24.5%) and combination 
(37%), allopathic and herbal medicines. Reasons behind usage of herbal medicines 
were, more efficacious and lesser side effects (34.07%) and followed by safer than 
conventional drugs (26.54%). Only 39.39% were having knowledge on dose, dura-
tion of therapy, side effects and drug interactions. Main sources of information 
about herbal medicines were found to be friends (32.74%) and drug advertisements 
(32.30%). Of 226 respondents only 65 (28.76%) of them could identify or felt ADRs. 
Out of 65, only 16 of them have reported to physician and 49 patients have taken 
their own decision.18 respondents chosen an alternative therapy, 14 stopped the 
medication, 9 and 8 reduced dosage without consultation and continued medica-
tion respectively. CONCLUSIONS: Overall the respondents of this study were using 
either herbal or combination medicines because they were considered as efficacious 
and have lesser side effects. However, their knowledge related to dose, duration of 
therapy, side effects and drug interaction was less. They were also less aware or 
couldn’t identify ADRs and the ones who were aware about the ADRs, decisions 
taken by them were found to be inappropriate.
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OBJECTIVES: The objective of this study was to evaluate access to healthcare provid-
ers before and after a significant increase in managed care (MC) enrollment in the 
Mississippi Medicaid program. METHODS: A retrospective analysis was conducted 
using Mississippi Medicaid fee-for-service (FFS) and MC pharmacy claims data in the 
period one year prior to (pre-period) and one year after (post-period) the December 
2012 Medicaid MC expansion. Beneficiaries had to be enrolled for at least one month 
during the study period to be included in the analysis. Providers were considered 
to be participating in a plan (FFS or MC) during each observation period if at least 
one pharmacy claim bearing his/her Medicaid provider identity number was filed 
during the period. Distance from beneficiary to provider was calculated by comput-
ing geocodes for their respective zip-codes using the PROC GEOCODE procedure in 
SAS. RESULTS: Overall, the average distance beneficiaries had to travel to see the 
three closest primary care providers (PCPs) or specialists who accept either FFS or 
Medicaid MC plans did not change significantly from the pre- to the post-period (10.2 
miles for PCPs and 7.7 miles for specialist). During the post-period in rural areas, 
beneficiaries in MC had slightly lower distances for PCPs (10.6 miles for MC and 
10.9 for FFS) and for specialist (8.6 miles for MC and 8.9 miles for FFS). Overall, the 
ratio of the number of enrollees per PCP significantly decreased for FFS (p< 0.01) and 
significantly increased for MC plan A and B (p< 0.01). The number of enrollees per 
specialist did not significantly change for FFS (p= 0.059) and significantly increased 
for MC plan A and B (p< 0.01) from the pre- to the post-period. CONCLUSIONS: 
Expansion of Medicaid MC has not adversely affected physician participation in 
Medicaid and in rural areas has slightly improved access to PCPs and specialists.
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OBJECTIVES: It is unknown if timely access to pharmacies differs based on demo-
graphic characteristics. The objective of this study was to determine if disparities 
exist in geographical accessibility to community and hospital pharmacies among 
patients in Hamilton County. METHODS: The Ohio State Board of Pharmacy pro-
vided a list of all the pharmacies in Hamilton County Ohio. The geographic distribu-
tion of the population in each census block group was based on data from Census 
2010. The address of each active pharmacy was geocoded using ArcMap. The loca-
tion of each pharmacy was used to identify the nearest pharmacy to the centroid 
of each census block group. Independent variables included in the study were age, 
gender and race, the dependent variable was travel time to the nearest pharmacy 
from the centroid of each block group. RESULTS: As of November 2014, there were 
173 active community and hospital pharmacies in Hamilton County. Ninety three 
percent of the population had at least one pharmacy within a 5 minute drive time. 
Travel time was 2.57 minutes for whites, 1.96 minutes for blacks (p= 0.0016). Males 
